FCFederico Conrotto

Federico Conrotto

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Federico Conrotto has a total of 31 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Transcatheter Aortic Valve Implantation for Pure Native Aortic Regurgitation: A Comprehensive State-of-the-Art Review

    by Joao Matteo Rampone, Samuele Sandrone, Sergio Capoccia, Federico Conrotto, Francesco Bruno, Ovidio De Filippo, Mario Iannaccone, Giacomo Boccuzzi, Fabrizio D’AScenzo, Francesco Maisano, et al.

    Pure native aortic regurgitation (AR) remains a challenging and frequently undertreated valvular disease, associated with substantial morbidity and mortality. Surgical aortic valve repair or replacement remains the standard of care; however, many patients are older, frail, or at prohibitive surgical risk, creating an unmet need for less invasive therapeutic options. In this context, transcatheter aortic valve implantation (TAVI) has progressively emerged as a potential alternative. However, the application of TAVI in AR has historically been limited by the absence of annular and leaflet calcification, the presence of large and often noncircular annuli, and the resulting risks of transcatheter valve embolization or migration, residual paravalvular regurgitation, and conduction disturbances. This review summarizes contemporary evidence on TAVI for pure native AR, spanning early off-label experience with first-generation self-expanding and balloon-expandable valves to newer-generation platforms and dedicated devices. Recent observational studies and multicenter registries have shown meaningful improvements in procedural success, lower rates of residual AR and second valve implantation, and acceptable short- and mid-term mortality with contemporary off-label devices. Dedicated systems, including JenaValve Trilogy, J-Valve, and others, have further enhanced anchoring and sealing performance, achieving markedly lower rates of valve migration and significant residual regurgitation. Nonetheless, permanent pacemaker implantation remains a major limitation for several platforms. In parallel, the AURORA trial introduced an anatomy-guided strategy based on multidetector computed tomography classification and dual anchoring theory, suggesting that careful anatomical selection and optimized implantation planning may improve outcomes even with non-dedicated devices. Overall, TAVI has become a viable option for selected high-risk patients with severe symptomatic pure native AR and has now been incorporated into contemporary guidelines in this setting. Future progress will likely depend on further refinement of dedicated devices, reduction of conduction-related complications, and broader integration of patient-specific anatomical and biomechanical assessment to optimize device selection and implantation strategy.

  • “Pressure Pressing Down on Me”

    by Paolo Boretto, Alessandro Depaoli, Federico Conrotto, Pierluigi Omedè, Ovidio De Filippo, Alessandro Serafini, Giulio Antonino Strazzarino, Paolo Fonio, Gaetano Maria De Ferrari, Fabrizio D’aScenzo


  • Left main occlusion secondary to infective endocarditis vegetation: “The unusual suspect”

    by Marco Pavani, Federico Conrotto, Fabrizio D'AScenzo, Maurizio D'AMico, Paolo Centofanti, Fiorenzo Gaita


  • Open Access

    The Prognostic Impact of High On-Treatment Platelet Reactivity with Aspirin or ADP Receptor Antagonists: Systematic Review and Meta-Analysis

    by Fabrizio D’aScenzo, Umberto Barbero, Marta Bisi, Claudio Moretti, Pierluigi Omedè, Enrico Cerrato, Giorgio Quadri, Federico Conrotto, Giuseppe Biondi Zoccai, James J. DiNicolantonio, et al.

    Objective. Negative results of recent randomized clinical trials testing the hypothesis of target therapy for patients with high on-treatment platelet reactivity (HOPR) have questioned its independent impact on clinical outcomes. 26 studies with 28.178 patients were included, with a median age of 66.8 (64–68) and 22.7% (22.4–27.8), of female gender. After a median follow-up of 1 year (0.1–1), cardiac adverse events occurred in 8.3% (3–11; all results are reported as median and interquartile range) of patients. Pooling all studies together, on-treatment platelet reactivity significantly increased the risk of adverse events (OR 1.33 [1.09, 1.64],I2=0%). However, a sensitivity analysis showed that HOPR did not increase the risk of adverse events for patients with ACS, AMI, or stable angina as well as patients resistant to aspirin, ADP antagonists, or both. For all studies, publication bias was formally evident; after adjusting for this, HOPR did not significantly increase adverse cardiac events (OR 1.1 : 0.89–1.22,I20%).Conclusions. After adjusting for clinical confounders (like risk factors and clinical presentation) and for relevant publication bias, HOPR was not an independent prognostic indicator in unselected patients with both stable and unstable coronary disease for an adverse cardiac event. The clinical importance of HOPR for high-risk populations remains to be assessed.